Advanced search
Publication Cover
Leukemia & Lymphoma Volume 18, 1995 - Issue 1-2
Submit an article Journal homepage
13
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Favorable Pharmacodynamic Features and Superior Anti-Leukemic Activity of B43 (Anti-CD 19) Immunotoxins Containing Two Pokeweed Antiviral Protein Molecules Covalently Linked to each Monoclonal Antibody Molecule

Dorothea E. Myers Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA
,
Yuri Yanishevski Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA
,
Eric Masson Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA
,
James D. Irvin Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA
,
William E. Evans Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA
&
Fatih M. Uckun Biotherapy Program, Departments of Therapeutic, Radiology-Radiation Oncology; Childrens Cancer Group Immunotoxin Resource Laboratory, Pharmaceutical Department, University of Minnesota, Minneapolis, Minnesota St. Jude Children's Research Hospital; Departments of Pediatrics, Memphis Department of Chemistry, University of Tennessee, Southwest Texas State University, San Marcos, Texas, USA; Clinical Pharmacy, Colleges of Pharmacy and MedicineMemphis University of Tennessee, Southwest Texas State University, Department of Chemistry, San Marcos, Texas, USA
Pages 93-102 | Received 16 Sep 1994, Published online: 01 Jul 2009

References

  • Champlin R., Gale R. P. Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 1989; 73: 2051–2066
  • Poplack D. G., Reaman G. Acute lymphoblastic leukemia in childhood. Pediatric Clinics of North America 1988; vol. 35(No. 4)903–932
  • Bleyer W. A., Sather H., Coccia P., Lukens J., Siegel S., Hammond D. The staging of childhood acute lymphoblastic leukemia: Strategies of the Childrens Cancer Study Group and a three dimensional technique of multivariate analysis. Med. Ped. Oncol 1986; 14: 271–280
  • Rivera G. K., Pinkel D., Simone J. V., Hancock M. L., Crist W. M. Treatment of Acute Lymphoblastic Leukemia. New Engl. J. Med 1993; 329: 1289–1295
  • Gaynon P., Bleyer W. A., Steinherz P., Finkelstein J., Littman P., Miller D., Reaman G., Sather H., Hammond D. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable features. Amer. J. Ped. Hematol. Oncol 1988; 10: 42–50
  • Steinherz P., Gaynon P., Miller D., Reaman G., Bleyer W. A., Finkelstein J., Evans R., Meyers P., Steinherz L., Sather H., Hammond D. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York Regimen—A new intensive therapy protocol. J. Clin. Oncol 1986; 4: 744–752
  • Uckun F. M., Kersey J. H., Haake R., Weisdorf D., Nesbit M., Ramsay N. K. C. Pretransplant leukemic progenitor cell burden as a predictor of relapse after autologous bone marrow transplantation for high risk remission acute lymphoblastic leukemia. New England Journal of Medicine 1993; 329: 1296–1301
  • Kersey J. H., Weisdorf D., Nesbit M., LeBien T. W., Woods W., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., Hurd D., Ramsay N. K. C. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukemia. New Engl. J. Med 1987; 317: 461–467
  • Pastan I., Willingham M. C., Fitzgerald J. P. Immunotoxins. Cell 1986; 47: 641–648
  • Grossbard M. L., Nadler L. M. Immunotoxin therapy of malignancy. Important Advances in Oncology 1992, V. T. DeVita, S. Heilman, S. A. Rosenberg. Lippincott, Philadelphia, PA 1992; 112–136
  • Uckun F. M. Immunotoxin therapy of human lymphoid malignancies. Brit. J. Haematol 1993; 85: 435–438
  • Uckun F. M., Frankel A. The current status of immunotoxins: An overview of experimental and clinical studies as presented at the Third International Symposium on Immunotoxins. Leukemia 1993; 7: 341–348
  • Irvin J. D., Uckun F. M. Pokeweed antiviral protein: Ribosome inactivation and therapeutic applications. Pharmacology and Therapeutics 1992; 55: 279–302
  • Uckun F. M., Gajl-Peczalska K. J., Kersey J. H., Houston L. L., Vallera D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. Journal of Experimental Medicine 1986; 163: 347–368
  • Uckun F. M., Jaszcz W., Ambrus J. L., Fauci A. S., Gajl-Peczalska K. J., Song C. W., Wick M. R., Myers D. E., Waddick K. G., Ledbetter J. A. Detailed studies on expression and function of CD19 surface determinant using B43 monoclonal antibody. Blood 1988; 71: 13–29
  • Uckun F. M., Manivel C., Arthur D., Chelstrom L., Finnegan D., Irvin J., Tuel-Ahlgren L., Myers D. E., Gunther R. In vivo efficacy of B43(anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–2214
  • Myers D. E., Irvin J. D., Smith R. S., Kuebelbeck V. M., Uckun F. M. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B-lineage lymphoid differentiation antigen in highly purified form for human clinical trials. Journal of Immunological Methods 1991; 136: 221–238
  • Uckun F. M., Myers D. E., Keubelbeck V. M., Irvin J. D., Finnegan D., Chelstrom L. M., Houston L. L. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity, and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin. Leukemia and Lymphoma 1993; 9: 459–476
  • D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Prog. Biomed 1979; 9: 115–134
  • Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Thomas E. D. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584
  • Ramakrishnan S., Houston L. L. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein antibody conjugates from blood. Cancer Res 1985; 45: 2031–2036
  • Wawrzynczak E. J., Thorpe P. E. Methods for preparing immunotoxins. Effect of the linkage on activity and stability. Immunotoxins, Antibody Conjugates in Radioimaging and Therapy of Cancer, ed. Carl-Wilhelm Vogel. 1987; p28
  • Blakey D. C., Watson G. J., Knowles P. P., Thorpe P. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-thy 1.1 antibody. Cancer Res 1987; 47: 947–952
  • Reimann K. A., Turner A., Lambert J. M., Reed M. H., Schlossman S. F., Letvin N. L. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. V. Evidence that humoral immune response to monoclonal antibodies and immunotoxin conjugates abrogates their cytotoxic activity. Transplantation 1989; 48: 906

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.